PainReform (PRFX) Short Interest Ratio & Short Volume

Short interest is the volume of PainReform shares that have been sold short but have not yet been closed out or covered. As of March 31st, traders have sold 16,400 shares of PRFX short. 1.21% of PainReform's shares are currently sold short. Learn More on PainReform's current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.21% of PainReform's floating shares are currently sold short.

PainReform saw a increase in short interest in March. As of March 31st, there was short interest totaling 16,400 shares, an increase of 18.0% from the previous total of 13,900 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

PainReform currently has issued a total of 2,030,000 shares. Some of PainReform's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. PainReform currently has a public float of 1,360,000 shares.

1.21% of PainReform's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to PainReform: NeuBase Therapeutics, Inc. (4.92%), 180 Life Sciences Corp. (8.36%), Baudax Bio, Inc. (1.11%), GRI Bio, Inc. (1.81%), Biodexa Pharmaceuticals Plc (5.18%), Galmed Pharmaceuticals Ltd. (1.10%), Panbela Therapeutics, Inc. (2.36%), Dermata Therapeutics, Inc. (1.73%), SciSparc Ltd. (24.15%), Comera Life Sciences Holdings, Inc. (2.38%),

As of the most recent reporting period, the following stocks had the largest short interest positions: TC Energy Co. ($4.49 billion), T-Mobile US, Inc. ($3.94 billion), General Motors ($3.34 billion), Charter Communications, Inc. ($3.32 billion), Occidental Petroleum Co. ($3.21 billion), Super Micro Computer, Inc. ($3.13 billion), Coinbase Global, Inc. ($3.08 billion), Moderna, Inc. ($2.28 billion), Tractor Supply ($2.24 billion), and Royal Caribbean Cruises Ltd. ($2.14 billion). View all of the most shorted stocks.

Short selling PRFX is an investing strategy that aims to generate trading profit from PainReform as its price is falling. PRFX shares are trading up $0.04 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for PainReform occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of PRFX, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including PRFX, twice per month. The most recent reporting period available is March, 31 2024.